{"effective_time":"20171211","id":"2f569c7e-bd37-4bb3-92db-caf575ef4381","openfda":{},"package_label_principal_display_panel":["PRINICPAL DISPLAY PANEL NDC 49702-231-13 Triumeq (abacavir, dolutegravir, and lamivudine) 600 mg/50 mg/300 mg TABLETS Each film-coated tablet contains abacavir sulfate equivalent to 600 mg of abacavir, dolutegravir sodium equivalent to 50 mg of dolutegravir, and 300 mg of lamivudine. Store in original package at controlled room temperature of 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) (See USP). Keep bottle tightly closed; protect from moisture. Do not remove desiccant. Do not use if printed safety seal under cap is broken or missing. See prescribing information for dosage information. Notice to Authorized Dispenser: Each time TRIUMEQ is dispensed, give the patient a Medication Guide and Warning Card from the carton. Rx only 30 Tablets 10000000147131 Rev. 8/17 Triumeq 30 count carton"],"set_id":"b38da720-b1b2-4b7e-93de-5063c67325fb","spl_product_data_elements":["Triumeq dolutegravir sodium, abacavir sulfate, lamivudine DOLUTEGRAVIR SODIUM DOLUTEGRAVIR ABACAVIR SULFATE ABACAVIR LAMIVUDINE LAMIVUDINE MANNITOL MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE POVIDONE, UNSPECIFIED SODIUM STARCH GLYCOLATE TYPE A CORN FERROSOFERRIC OXIDE FERRIC OXIDE RED POLYETHYLENE GLYCOL, UNSPECIFIED POLYVINYL ALCOHOL, UNSPECIFIED TALC TITANIUM DIOXIDE 572;Tri"],"version":"2"}